Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/408
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMOLENBERGHS, Geert-
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorGEYS, Helena-
dc.contributor.authorRENARD, Didier-
dc.contributor.authorBURZYKOWSKI, Tomasz-
dc.contributor.authorALONSO ABAD, Ariel-
dc.date.accessioned2004-10-29T08:59:01Z-
dc.date.available2004-10-29T08:59:01Z-
dc.date.issued2002-
dc.identifier.citationControlled Clinical Trials, 23(6), PII S0197-2456(02)00236-2. p. 607-625-
dc.identifier.issn0197-2456-
dc.identifier.urihttp://hdl.handle.net/1942/408-
dc.description.abstractThe validation of surrogate endpoints has been studied by Prentice, who presented a definition as well as a set of criteria that are equivalent if the surrogate and true endpoints are binary. Freedman et al. supplemented these criteria with the so-called proportion explained. Buyse and Molenberghs proposed to replace the proportion explained by two quantities: (1) the relative effect, linking the effect of treatment on both endpoints, and (2) the adjusted association, an individual-level measure of agreement between both endpoints. In a multiunit setting, these quantities can be generalized to a trial-level measure of surrogacy and an individual-level measure of surrogacy. In this paper, we argue that such a multiunit approach should be adopted because it overcomes difficulties that necessarily surround validation efforts based on a single trial. These difficulties are highlighted.-
dc.description.sponsorshipDr. Geys is supported by a grant from IWT — Vlaanderen. Drs. Burzykowski and Alonso are supported by an LUC Bijzonder Onderzoeksfonds grant.-
dc.language.isoen-
dc.rights(C) 2002 Elsevier Science Inc. All rights reserved.-
dc.subjectClinical trials-
dc.subjectClustered data-
dc.subjectSurrogate Markers-
dc.subject.otheradjusted association; meta-analysis; proportion explained; random-effects model; relative effect; surrogate endpoint; validation-
dc.titleStatistical challenges in the evaluation of surrogate endpoints in randomized trials-
dc.typeJournal Contribution-
dc.identifier.epage625-
dc.identifier.issue6-
dc.identifier.spage607-
dc.identifier.volume23-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.bibliographicCitation.oldjcatA1-
local.bibliographicCitation.artnrPII S0197-2456(02)00236-2-
dc.identifier.doi10.1016/S0197-2456(02)00236-2-
dc.identifier.isi000179835100001-
dc.identifier.urlhttps://www.academia.edu/8393370/Statistical_challenges_in_the_evaluation_of_surrogate_endpoints_in_randomized_trials-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
item.fullcitationMOLENBERGHS, Geert; BUYSE, Marc; GEYS, Helena; RENARD, Didier; BURZYKOWSKI, Tomasz & ALONSO ABAD, Ariel (2002) Statistical challenges in the evaluation of surrogate endpoints in randomized trials. In: Controlled Clinical Trials, 23(6), PII S0197-2456(02)00236-2. p. 607-625.-
item.validationecoom 2004-
item.contributorMOLENBERGHS, Geert-
item.contributorBUYSE, Marc-
item.contributorGEYS, Helena-
item.contributorRENARD, Didier-
item.contributorBURZYKOWSKI, Tomasz-
item.contributorALONSO ABAD, Ariel-
crisitem.journal.issn0197-2456-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
1-s2.0-S0197245602002362-main.pdfPublished version119.35 kBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

91
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

81
checked on May 8, 2024

Page view(s)

62
checked on Sep 6, 2022

Download(s)

264
checked on Sep 6, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.